{{Rsnum
|rsid=951436
|Chromosome=1
|position=163063552
|Orientation=plus
|GMAF=0.4265
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 29.2 | 52.3 | 18.5
| HCB | 13.3 | 55.6 | 31.1
| JPT | 27.3 | 54.5 | 18.2
| YRI | 66.7 | 28.6 | 4.8
| ASW | 0.0 | 0.0 | 0.0
| CHB | 13.3 | 55.6 | 31.1
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=20414142
|Title=Association study between RGS4 and bipolar disorder in the Chinese Han population
}}

{{PMID|16905560}} RGS4 mRNA expression in postmortem human cortex is associated with COMT Val158Met genotype and COMT enzyme activity.

{{PMID|17092693}} RGS4 is not a susceptibility gene for schizophrenia in Japanese: association study in a large case-control population.

{{PMID|17301167}} Allelic variation in RGS4 impacts functional and structural connectivity in the human brain.

{{PMID|17588543|OA=1
}} Ethnic stratification of the association of RGS4 variants with antipsychotic treatment response in schizophrenia.

{{PMID|18434012}} RGS4 polymorphism and response to electroconvulsive therapy in major depressive disorder.

{{PMID|18804346|OA=1
}} Interaction between interleukin 3 and dystrobrevin-binding protein 1 in schizophrenia.

{{PMID|18834502|OA=1
}} Association of RGS4 variants with schizotypy and cognitive endophenotypes at the population level.

{{PMID|19693005|OA=1
}} Executive function, neural circuitry, and genetic mechanisms in schizophrenia.

{{PMID|22157635}} Lack of association between the regulator of G-protein signaling 4 (RGS4) rs951436 polymorphism and schizophrenia.

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}